Home » Stocks » Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)

Stock Price: $71.20 USD -1.19 (-1.64%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.17B
Revenue (ttm) 1.15M
Net Income (ttm) -351.56M
Shares Out 58.29M
EPS (ttm) -12.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $71.20
Previous Close $72.39
Change ($) -1.19
Change (%) -1.64%
Day's Open 72.99
Day's Range 69.92 - 73.11
Day's Volume 434,035
52-Week Range 26.56 - 76.40

More Stats

Market Cap 4.17B
Enterprise Value 3.74B
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 58.29M
Float 50.30M
EPS (basic) -7.89
EPS (diluted) -12.41
FCF / Share -8.99
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.31M
Short Ratio 13.62
Short % of Float 24.25%
Beta 1.41
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3,620.76
PB Ratio 34.98
Revenue 1.15M
Operating Income -321.03M
Net Income -351.56M
Free Cash Flow -507.30M
Net Cash 428.24M
Net Cash / Share 7.32
Gross Margin -25,126.15%
Operating Margin -27,891.66%
Profit Margin -30,543.40%
FCF Margin -44,074.37%
ROA -92.51%
ROE -584.04%
ROIC 989.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(18.26% upside)
Current: 71.20
Target: 84.20
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-225-108-108-60.64-9.70
Net Income-241-127-127-63.53-10.07
Shares Outstanding39.1927.8527.8512.6111.01
Earnings Per Share-6.15-5.00-5.00-5.05-0.91
Operating Cash Flow-377-197-94.82-29.50-5.63
Capital Expenditures-3.78-4.17-0.54-0.03-
Free Cash Flow-381-201-95.36-29.53-5.63
Cash & Equivalents31726413123.571.46
Total Debt---4.81-
Net Cash / Debt31726413118.751.46
Book Value-7.42151132-45.031.14
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Biohaven Pharmaceutical Holding Co. Ltd.
Country United States
Employees 647
CEO Vlad Coric

Stock Information

Ticker Symbol BHVN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: BHVN
IPO Date May 4, 2017


Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.